News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,912 Results
Type
Article (14894)
Company Profile (299)
Press Release (266713)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79930)
Career Advice (163)
Deals (13359)
Drug Delivery (39)
Drug Development (50703)
Employer Resources (31)
FDA (5844)
Job Trends (5176)
News (145210)
Policy (10083)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21790)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6039)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4567)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3129)
Cardiovascular disease (237)
Career advice (148)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43674)
Collaboration (1148)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4320)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (214)
Earnings (31690)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51724)
Executive appointments (622)
FDA (7592)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6618)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7361)
IRA (12)
Job creations (869)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1403)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6621)
Metabolic disorders (724)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (329)
Peanut (43)
People (26669)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15476)
Phase 2 (20290)
Phase 3 (12824)
Pipeline (3248)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1450)
Recruiting (12)
Regulatory (9903)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (13)
Last 7 days (343)
Last 30 days (1128)
Last 365 days (17811)
2026 (1665)
2025 (18100)
2024 (20551)
2023 (22419)
2022 (26827)
2021 (27809)
2020 (23367)
2019 (16248)
2018 (11763)
2017 (13756)
2016 (11859)
2015 (14366)
2014 (10400)
2013 (7517)
2012 (7582)
2011 (7668)
2010 (7457)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18253)
Australia (3111)
California (7074)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39166)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5583)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1646)
New Mexico (13)
New York (1762)
North Carolina (827)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (41)
Texas (909)
United States (23336)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,912 Results for "revance therapeutics inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Revance and Teoxane Announce the FDA Approval of RHA® Dynamic Volume for Midface Contour Deficiencies
January 14, 2026
·
10 min read
Mergers & acquisitions
Crown Laboratories to Buy Botox Rival Revance Therapeutics for $924M
The acquisition announced Monday will give Crown access to Revance’s Daxxify, a competitor to AbbVie’s Botox, which is indicated for frown lines and for cervical dystonia.
August 13, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Crown Laboratories Completes Acquisition of Revance Therapeutics
February 7, 2025
·
3 min read
Press Releases
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
February 5, 2025
·
5 min read
Press Releases
Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
February 6, 2025
·
4 min read
BioMidwest
Revance to Participate in Upcoming June 2024 Investor Conferences
Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.
May 28, 2024
·
1 min read
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced the commercial launch of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and disabling chronic condition.
May 9, 2024
·
11 min read
BioMidwest
Revance to Participate in Upcoming March 2024 Investor Conferences
Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.
February 21, 2024
·
1 min read
Deals
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock.
March 4, 2024
·
4 min read
BioMidwest
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 14, 2024
Revance Therapeutics, Inc. announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units to 31 employees.
June 14, 2024
·
5 min read
1 of 28,192
Next
